United States: Supreme Court Hears Arguments In "FTC v. Actavis"

Last Updated: April 9 2013
Article by Erin E. Bryan and Paul M. Rivard

On March 25, 2013, the Supreme Court heard oral arguments in Federal Trade Commission v. Actavis, a case involving a circuit split regarding "pay for delay" settlements within the pharmaceutical industry. Justice Alito previously recused himself from the case.

The Supreme Court seeks to resolve a split among the circuits as to whether a brand name drug manufacturer acts illegally by paying a competing generic drug manufacturer to stay out of the market for a specified number of years. The Eleventh Circuit favors a "scope-of-the-patent" rule in analyzing pay for delay settlements, while the Third Circuit has suggested that a "quick look" rule is the better option.

During oral arguments, several of the justices seemed skeptical that a special rule should be adopted for analyzing reverse payment agreements. At the same time, the Supreme Court also appeared concerned about the effect pay for delay settlements have on consumers. Because the Supreme Court is ruling on this case with eight justices, it is possible the case decision may be split 4-4, thereby leaving in place a split among the circuits.

The reverse payment settlement agreement

In the pending case, Solvay Pharmaceuticals, Inc., applied for and obtained a patent directed to certain pharmaceutical formulations utilized in AndroGel®, which provides a treatment for low testosterone in men. After the patent was granted and made known to the FDA, Watson Pharmaceuticals (now Actavis, Inc.) and Paddock Laboratories, Inc., submitted separate abbreviated new drug applications (ANDAs) seeking approval for a generic version of AndroGel®. Each ANDA included a paragraph IV certification asserting that the proposed generic product would not infringe Solvay's patent and that the patent was invalid. Soon after Paddock submitted its ANDA, they agreed to partner with Par Pharmaceutical Companies, Inc., by sharing in litigation costs and eventually promoting Paddock's generic version of AndroGel®.

Solvay sued Watson and Paddock for patent infringement based on the paragraph IV certifications. While the patent litigation was still pending, the FDA approved Watson's ANDA. After receiving approval of the ANDA, Watson and Paddock expected to enter the market and begin selling their respective generic products within the year. Solvay initiated a settlement with Watson and Paddock/Par where Watson and Paddock/Par agreed to defer their market entry until 2015. In return, Solvay agreed to pay an estimated $19-30 million annually to Watson, $2 million annually to Paddock and $10 million annually to Par. The FTC filed suit challenging the settlement and asserting unfair methods of competition and an unlawful extension of the AndroGel® monopoly.

The district court dismissed the FTC's complaint for failure to state a claim. This decision was affirmed by the Eleventh Circuit. The Eleventh Circuit stated that "absent sham litigation or fraud in obtaining the patent, a reverse payment settlement is immune from antitrust attack so long as its anticompetitive effects fall within the scope of the exclusionary potential of the patent." This view is commonly referred to as the "scope-of-the-patent" approach.

Shortly after the Eleventh Circuit's decision, the Third Circuit rejected the "scope-of-the-patent" approach and instead applied a different test in deciding In re K-Dur Antitrust Litigation. The Third Circuit stated that reverse payment agreements should be subject to a "quick look of reason analysis" under which "any payment from a patent holder to a generic patent challenger who agrees to delay entry into the market [is] prima facie evidence of an unreasonable restraint of trade."

The split between the Eleventh Circuit and the Third Circuit has raised the question as to whether reverse payment agreements are either per se unlawful unless the underlying patent litigation was a sham or the patent obtained by fraud, or instead, are presumptively anticompetitive and unlawful. In other words, does a brand name drug manufacturer act illegally by paying a competing generic drug manufacturer to stay out of the market for a specified number of years?

Arguments made by the government

The FTC states that the "scope-of-the-patent" rule applied by the Eleventh Circuit provides no meaningful antitrust scrutiny to the settlement agreements between drug manufacturers. The lack of antitrust scrutiny leads to an increase in reverse payment agreements, which allegedly causes a substantial increase in prescription costs for consumers.

Instead, the FTC would treat reverse payment agreements as presumptively anti-competitive under the "quick look" rule. Drug companies would then have the opportunity to rebut that presumption. The burden would be on the drug companies to show that any money that changed hands was for something other than a delay of entry into the market, such as some specific property or services unrelated to competition. The drug companies could also show that any payment from one party to another was commensurate with litigation costs that were avoided by settlement.

During oral argument, the Deputy Solicitor General argued that payments given to a potential competitor in exchange for staying out of the market violate basic antitrust principles, comparing reverse payment agreements to price fixing. The government pointed out that if the patent litigation were to proceed to conclusion, no possible outcome would involve payments going from the patentee to the generic manufacturer.

Arguments made by the drug companies

In contrast, the respondents Solvay, Watson and Paddock/Par state that the "quick look" test favored by the FTC is unworkable, especially in the generic drug context because it would require the court to conduct an analysis on the underlying patent's strength and validity. Rather, the drug companies favor a "scope-of-the-patent" approach to drug patent settlements. Settlements within the scope of the patent may be subject to antitrust scrutiny, but unlawful anticompetitive conduct can be found only where the underlying patent litigation is a sham or the patent was obtained by fraud.

The drug companies additionally point out that the FTC appears to be overlooking the rights that are obtained with a patent. Specifically, that a patent is presumed valid, and a patent allows for the exclusion of would-be competitors during the life of the patent, such as through the use of settlement agreements. In this case, Solvay agreed to permit market entry to Watson and Paddock/Par five years before the expiration of the patent at issue, or within the life of the patent.

Counsel argued for the respondents that Supreme Court precedent consistently requires restraints going beyond the exercise of the scope of the patent right for an antitrust violation to be found. Counsel urged that reverse payment agreements do not intrinsically present risks of anticompetitive conduct, noting that a typical patent settlement agreement involving a period of delay before market entry followed by payment of a royalty could be viewed in the same light since the infringer conceivably could have bargained for a lower royalty rate in exchange for delaying its market entry.

The Supreme Court's response

Several of the justices during arguments appeared reluctant to adopt a rule that reverse payment agreements are presumptively anticompetitive. Justice Breyer suggested that judges are capable of identifying collusive agreements to divide profits and questioned why the standard antitrust "rule of reason" analysis was inadequate.

Justice Sotomayor also pointed out that per se rules in antitrust law are uncommon. On the other hand, she questioned whether an agreement would be considered anticompetitive if a patentee knew it had only a 50 percent chance of prevailing in the infringement action and offered the generic company a substantial payment in exchange for not pursuing the litigation. Counsel for the respondents argued the patentee would need to pay off a large number of generics in this situation, and doing so would not be cost effective.

Another theme that came out during arguments was that Hatch-Waxman is designed to encourage the challenge of patents by generics. The Deputy Solicitor General argued the type of settlements at issue interferes with such challenges, to the detriment of consumers. Counsel for the respondents pointed out that most patent infringement suits settle, and that the nature of the settlements under Hatch-Waxman is a direct result of the legislative framework itself. Counsel urged that if a problem exists, it should be corrected by legislation rather than the court fashioning a special antitrust rule.

The court is expected to issue its decision later in 2013.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions